Coverage: LD-2 reports for 2025 onward, posted Jan 1, 2025 through Oct 28, 2026. Only the current version of each report is used.
51,839 report citations, newest first.
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$730,000
Spent on own lobbying
CitesH.R. 1492· this member:Cosponsored
P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; relating to Title VII, Subtitle B H.R. 1492: To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiatio…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$730,000
Spent on own lobbying
CitesH.R. 1· this member:Recorded votes on 3 roll calls
P.L. 119-21 (H.R. 1): One Big Beautiful Bill Act; provisions related to Title VII, Subtitle B H.R. 946: Orphan CURES Act; all provisions H.R. 2214: DRUG Act; all provisions H.R. 4…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
$730,000
Spent on own lobbying
CitesH.R. 6703· this member:Recorded votes on 2 roll calls
…lated to Title VII, Subtitle B H.R. 946: Orphan CURES Act; all provisions H.R. 2214: DRUG Act; all provisions H.R. 4317: PBM Reform Act of 2025; all provisions H.R. 6703: Lower Health Care Premiums for All Americans Act; provisions related to Pharmacy Benefit Management (PBM) S. 864: HELP Copays Act; all provisions S. 882: Pati…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$730,000
Spent on own lobbying
CitesH.R. 3838· this member:Recorded votes on 19 roll calls
H.R. 3838: Streamlining Procurement for Effective Execution and Delivery and National Defense Authorization Act for Fiscal Year 2026; provisions related to Military acce…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$730,000
Spent on own lobbying
CitesH.R. 8800· this member:Recorded votes on 21 roll calls
…ization Act for Fiscal Year 2026; provisions related to Military access to infertility care H.R. 6797: Bipartisan IVF for Military Families Act; all provisions H.R. 8800: National Defense Authorization Act for Fiscal Year 2027; provisions related to Military access to infertility care S. 1071: National Defense Authorization Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
EMD SERONO INC · lobbying firm or registrant: EMD SERONO, INC.
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$730,000
Spent on own lobbying
CitesS. 1071· this member:Recorded votes on 2 roll calls
…tary Families Act; all provisions H.R. 8800: National Defense Authorization Act for Fiscal Year 2027; provisions related to Military access to infertility care S. 1071: National Defense Authorization Act for Fiscal Year 2026; provisions related to Military access to infertility care S. 2296: National Defense Authorization Act…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INVEST IN EDUCATION COALITION · lobbying firm or registrant: MICHAEL BEST STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$20,000
Paid to lobbying firm
CitesH.R. 1· this member:Recorded votes on 3 roll calls
Issues related to primary education, regulations related to the scholarship tax credit provision in P.L. 119-21 (H.R. 1).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · lobbying firm or registrant: MARSHALL & POPP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$40,000
Paid to lobbying firm
CitesH.R. 1492· this member:Cosponsored
…flation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Issues related to vaccine developm…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PFIZER, INC. · lobbying firm or registrant: MARSHALL & POPP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
CitesH.R. 1492· this member:Cosponsored
…flation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine developme…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SENTRY INSURANCE COMPANY · lobbying firm or registrant: ARNOLD & PORTER KAYE SCHOLER LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Insurance
$60,000
Paid to lobbying firm
CitesH.R. 7128· this member:Recorded vote on 1 roll call
…ssues related to insurance industry, including within the One Big Beautiful Bill Act (P.L. 119-21) and the Terrorism Risk Insurance Act (TRIA) reauthorization (H.R.7128/S.4395).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL LEGAL FINANCE ASSOCIATION · lobbying firm or registrant: ONMESSAGE PUBLIC STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$60,000
Paid to lobbying firm
CitesH.R. 1109· this member:Cosponsored
Issues related to business taxation and litigation financing (H.R. 3512/S. 1821, Tackling Predatory Litigation Act; H.R. 7015 Protecting TPLF From Abuse Act; H.R. 1109 Litigation Transparency Act of 2025).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL LEGAL FINANCE ASSOCIATION · lobbying firm or registrant: ONMESSAGE PUBLIC STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Taxation/Internal Revenue Code
$60,000
Paid to lobbying firm
CitesH.R. 7015· this member:Cosponsored
Issues related to business taxation and litigation financing (H.R. 3512/S. 1821, Tackling Predatory Litigation Act; H.R. 7015 Protecting TPLF From Abuse Act; H.R. 1109 Litigation Transparency Act of 2025).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL LEGAL FINANCE ASSOCIATION · lobbying firm or registrant: ONMESSAGE PUBLIC STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$60,000
Paid to lobbying firm
CitesH.R. 1109· this member:Cosponsored
Issues related to business taxation and litigation financing (H.R. 3512/S. 1821, Tackling Predatory Litigation Act; H.R. 7015 Protecting TPLF From Abuse Act; H.R. 1109 Litigation Transparency Act of 2025).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
INTERNATIONAL LEGAL FINANCE ASSOCIATION · lobbying firm or registrant: ONMESSAGE PUBLIC STRATEGIES
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$60,000
Paid to lobbying firm
CitesH.R. 7015· this member:Cosponsored
Issues related to business taxation and litigation financing (H.R. 3512/S. 1821, Tackling Predatory Litigation Act; H.R. 7015 Protecting TPLF From Abuse Act; H.R. 1109 Litigation Transparency Act of 2025).
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STARKEY LABORATORIES, INC. · lobbying firm or registrant: DUDDINGTON GLOBAL STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$20,000
Paid to lobbying firm
CitesH.R. 1968· this member:Recorded votes on 2 roll calls
…s matters, including National Defense Authorization Act (NDAA) for Fiscal Year 2025 (PL 118-159), Full Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968), National Defense Authorization Act (NDAA) for Fiscal Year 2026 (no bill number).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
STARKEY LABORATORIES, INC. · lobbying firm or registrant: DUDDINGTON GLOBAL STRATEGIES LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Veterans
$20,000
Paid to lobbying firm
CitesH.R. 1968· this member:Recorded votes on 2 roll calls
…s matters, including National Defense Authorization Act (NDAA) for Fiscal Year 2025 (PL 118-159), Full Year Continuing Appropriations and Extensions Act, 2025 (H.R. 1968), National Defense Authorization Act (NDAA) for Fiscal Year 2026 (no bill number).
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
CALIFORNIA RECYCLING ALLIANCE · lobbying firm or registrant: RIDGELINE ADVOCACY GROUP LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$40,000
Paid to lobbying firm
CitesH.R. 8800· this member:Recorded votes on 21 roll calls
H.R. 8800, FY27 National Defense Authorization Act S.4784, FY27 National Defense Authorization Act Issues related to defense industrial base supply chain, scrap metal re…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GRAIL, INC. · lobbying firm or registrant: MARSHALL & POPP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Medicare/Medicaid
$60,000
Paid to lobbying firm
CitesH.R. 7148· this member:Recorded votes on 4 roll calls
Issues related to cancer screening, including the implementation of Section 6221 of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GENENTECH, INC. · lobbying firm or registrant: MARSHALL & POPP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
CitesH.R. 1492· this member:Cosponsored
…flation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to FDA regulation of…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
GENENTECH, INC. · lobbying firm or registrant: MARSHALL & POPP, LLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Pharmacy
$60,000
Paid to lobbying firm
CitesH.R. 7148· this member:Recorded votes on 4 roll calls
…ated to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including Division J of H.R.7148 - Consolidated Appropriations Act, 2026, PL 119-75. Issues related to the 340B program.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
VISA · lobbying firm or registrant: WILLIAMS AND JENSEN, PLLC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Financial Institutions/Investments/Securities
$50,000
Paid to lobbying firm
CitesH.R. 3633· this member:Recorded vote on 1 roll call
…elating to the Credit Card Competition Act. S. 3623 & H.R. 7035. S. 394. PL 119-27 Guiding and Establishing National Innovation for US Stablecoin (GENIUS) Act. H.R. 3633, the Digital Asset Market Clarity (CLARITY) Act.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HOPE THROUGH HOUSING FOUNDATION · lobbying firm or registrant: GRAYROBINSON PA
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Budget/Appropriations
CitesH.R. 6644· this member:Recorded votes on 2 roll calls
Federal funding to support expanded residential services for residents of affordable housing communities. H.R.6644, 21st Century ROAD to Housing Act, provisions related to affordable housing. H.R. 4874, Affordable Housing Resident Services Act, all provisions.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
CHRONIC CARE POLICY ALLIANCE · lobbying firm or registrant: CHRONIC CARE POLICY ALLIANCE
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Health Issues
CitesH.R. 3514· this member:Cosponsored
SB 864 - HELP Copays Act HR 946 - Orphan Cures Act SB 832/ HR 1492 - EPIC Act HR 1520 - Charlotte Woodward Organ Transplant Discrimination Prevention Act HR 3514 - Improving Seniors Timely Access to Care Act of 2025 SB 2426 - Equitable Community Access to Pharmacist Services Act H.R. 3826/ S.B. 1925 - Expanding Access t…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. View filing
PLANET LABS PBC · lobbying firm or registrant: PLANET LABS PBC
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Defense
$390,000
Spent on own lobbying
CitesH.R. 8800· this member:Recorded votes on 21 roll calls
Satellite issues; Geospatial imagery; Defense programs and budget for commercial remote sensing; H.R. 8800, National Defense Authorization Act for FY27; S. 4784, National Defense Authorization Act for FY27; H.R. 9495, Department of Defense Appropriations Act, 2027.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SPECIALTY EQUIPMENT MARKET ASSOCIATION · lobbying firm or registrant: SPECIALTY EQUIPMENT MARKET ASSOCIATION
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · amended · posted Oct 20, 2026 · issue area: Small Business
$395,000
Spent on own lobbying
CitesH.R. 425· this member:Cosponsored
HR 421, Small Business Regulatory Flexibility Improvements Act S 100/HR 425, Repealing Big Brother Overreach Act S 505/HR 736, Protect Small Businesses from Excessive Paperwork Act of 2025 HR 832, Small Business Advocacy Improvements A…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
